Business Context and Reporting Period
Company: Coherus BioSciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 4, 2018
Reporting Period: Fourth Quarter 2017 and year-end position as of December 31, 2017.
Key Financial Metrics
| Metric | Value |
|---|---|
| Cash and Cash Equivalents (as of Dec 31, 2017) | $126.9 million |
| Cash Used for Operations and Equipment Investments (Q4 2017) | $30.2 million |
| Revenue, Profit, Margins, Debt | Not provided in this filing |
Material Changes and Operational Updates
- Liquidity Position: The Company maintained a cash balance of approximately $126.9 million at the end of 2017.
- Cash Burn: Approximately $30.2 million was utilized during the fourth quarter of 2017 for operational activities and equipment investments.
- Regulatory Milestone: Received a scheduling notice from the U.S. Food and Drug Administration (FDA) for a Type 2 meeting regarding the CHS-1701 pegfilgrastim biosimilar candidate.
- Meeting Timing: The FDA meeting is scheduled for the middle of the first quarter of 2018.
Guidance, Outlook, and Management Commentary
Regulatory Outlook: Management anticipates filing the Biologics License Application (BLA) for CHS-1701 following two key events: receipt of meeting minutes from the FDA and the completion of certain clinical sample analyses.
Risks and Contingencies: The filing does not explicitly detail new risks or contingencies beyond the standard regulatory approval process for the biosimilar candidate.
Key Facts for Investor Verification
- Verify the exact date of the FDA Type 2 meeting scheduled for Q1 2018.
- Confirm the status of clinical sample analyses required prior to the BLA filing.
- Monitor subsequent filings for the official BLA submission date for CHS-1701.
- Review the full 10-K or 10-Q for detailed revenue, expense, and debt metrics not included in this 8-K.